Recent Advances in Immunotherapy for Breast Cancer: A Review.

IF 3.3 4区 医学 Q2 ONCOLOGY Breast Cancer : Targets and Therapy Pub Date : 2024-08-27 eCollection Date: 2024-01-01 DOI:10.2147/BCTT.S482504
Qian-Er Wen, Liang Li, Rui-Qi Feng, De-Hui Li, Chang Qiao, Xiao-Song Xu, Yan-Jing Zhang
{"title":"Recent Advances in Immunotherapy for Breast Cancer: A Review.","authors":"Qian-Er Wen, Liang Li, Rui-Qi Feng, De-Hui Li, Chang Qiao, Xiao-Song Xu, Yan-Jing Zhang","doi":"10.2147/BCTT.S482504","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer is one of the most common malignant tumors in women in the world, and its incidence is increasing year by year, which seriously threatens the physical and mental health of women. Triple negative breast cancer (TNBC) is a special molecular type of breast cancer in which estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 are negative. Compared with other molecular types of breast cancer, triple-negative breast cancer (TNBC) has high aggressiveness and metastasis, high recurrence rate, lack of effective therapeutic targets, and usually poor clinical treatment effect. Chemotherapy was the main therapeutic means used in the past. With the advent of the immune era, immunotherapy has made a lot of progress in the treatment of triple-negative breast cancer (TNBC), bringing new therapeutic hope for the treatment of triple-negative breast cancer. This review combines the results of cutting-edge medical research, mainly summarizes the research progress of immunotherapy, and summarizes the main treatment methods of triple-negative breast cancer (TNBC) immunotherapy, including immune checkpoint inhibitors, tumor vaccines, adoptive immunotherapy and the application of traditional Chinese and western medicine. It provides a new idea for the treatment of triple negative breast cancer (TNBC).</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"497-516"},"PeriodicalIF":3.3000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365501/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/BCTT.S482504","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Breast cancer is one of the most common malignant tumors in women in the world, and its incidence is increasing year by year, which seriously threatens the physical and mental health of women. Triple negative breast cancer (TNBC) is a special molecular type of breast cancer in which estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 are negative. Compared with other molecular types of breast cancer, triple-negative breast cancer (TNBC) has high aggressiveness and metastasis, high recurrence rate, lack of effective therapeutic targets, and usually poor clinical treatment effect. Chemotherapy was the main therapeutic means used in the past. With the advent of the immune era, immunotherapy has made a lot of progress in the treatment of triple-negative breast cancer (TNBC), bringing new therapeutic hope for the treatment of triple-negative breast cancer. This review combines the results of cutting-edge medical research, mainly summarizes the research progress of immunotherapy, and summarizes the main treatment methods of triple-negative breast cancer (TNBC) immunotherapy, including immune checkpoint inhibitors, tumor vaccines, adoptive immunotherapy and the application of traditional Chinese and western medicine. It provides a new idea for the treatment of triple negative breast cancer (TNBC).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺癌免疫疗法的最新进展:综述。
乳腺癌是世界上女性最常见的恶性肿瘤之一,其发病率呈逐年上升趋势,严重威胁着女性的身心健康。三阴性乳腺癌(TNBC)是雌激素受体、孕激素受体和人表皮生长因子受体-2均为阴性的一种特殊的乳腺癌分子类型。与其他分子类型的乳腺癌相比,三阴性乳腺癌(TNBC)具有侵袭性和转移性强、复发率高、缺乏有效治疗靶点等特点,临床治疗效果通常较差。化疗是过去的主要治疗手段。随着免疫时代的到来,免疫治疗在三阴性乳腺癌(TNBC)的治疗中取得了很大进展,为三阴性乳腺癌的治疗带来了新的希望。本综述结合前沿医学研究成果,主要总结了免疫治疗的研究进展,归纳了三阴性乳腺癌(TNBC)免疫治疗的主要治疗方法,包括免疫检查点抑制剂、肿瘤疫苗、采用性免疫治疗和中西医结合应用等。为三阴性乳腺癌(TNBC)的治疗提供了新思路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
40
审稿时长
16 weeks
期刊最新文献
A Prospective Tumour Marker for Breast Cancer: YWHAB and Its Role in Promoting Oncogenic Phenotypes. The Clinical Study of Intratumoral and Peritumoral Radiomics Based on DCE-MRI for HER-2 Positive and Low Expression Prediction in Breast Cancer. Exploring the Complexity of Pan-Cancer: Gene Convergences and in silico Analyses. Comparison of Hematological Parameters and the Associated Factors Among Women with and without Breast Cancer: A Case-Control Study. A Novel Peroxisome-Related Gene Signature Predicts Breast Cancer Prognosis and Correlates with T Cell Suppression.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1